Enter Symbol:
INTERLEUKIN GENETICS INC
Diagnostic Substances
ILI @ Yahoo Finance ILI Option @ Yahoo Finance
Stock Details
Current Price	High	Value Change	Percent Change	Dividend	Previous Close
$ 0.40	$ 0.42	$ 0.01	2.12%	0.00	$ 0.39
Opening Price	Low	Volume	Market Cap	Average Volume	P/E
$ 0.38	$ 0.38	41,900	14.6M	45,000	-1.48
Pivot Table
R2 R1 Pivot S1 S2 0.44 0.42 0.40 0.38 0.36

Interleukin Genetics, Inc. focuses on developing, acquiring, and commercializing personalized health products for individuals to maintain their health through preventive measures. The company uses functional genomics to help in the development of risk assessment tests based on the genetic variations in people. It also develops and markets nutritional and OTCeutical products. Interleukin Genetics commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. The company sells its nutritional product brands, including Ginkoba, Ginsana, and Venastat through food, drug, and mass retailers. Its development programs focus on osteoporosis and weight management genetic risk assessment tests, as well as on its new proprietary OTCeuticals. Interleukin Genetics has a strategic alliance with the Alticor, Inc. to develop and market genetic risk assessment tests, and nutritional and skin care products; and a research agreement with Access Business Group LLC for development of genetic tests to guide consumers' selection of appropriate skin care products. It also has academic research collaborations with University of Sheffield, Tufts University, Harvard University, the Mayo Clinic, California Pacific Medical Center, Boston University, the University of Arkansas, Tongji Medical College, and Yonsei University. The company was founded in 1986 and is based in Waltham, Massachusetts.